. Author manuscript; available in PMC: 2013 Jan 28.

Published in final edited form as: Am J Manag Care. 2011 Jun;17(Suppl 8):S222–S234.

Table 2.

Persistence Survival Analysis to compare the risk of discontinuing AUD medication among study groups over the 6-month follow-up period.^a

Study Group	Hazard Ratio (95% CI) for Treatment Discontinuation
Study Group	Comparison with XR-NTX	Comparison with Oral NTX
XR-NTX	Reference	0.79 (0.70 to 0.89)^**
Oral NTX	1.27 (1.12 to 1.43)^**	Reference
Acamprosate	1.49 (1.32 to 1.67)^**	1.17 (1.11 to 1.23)^**
Disulfiram	1.47 (1.30 to 1.66)^**	1.16 (1.09 to 1.23)^**

Cox proportional hazards model compares study groups on the basis of time to treatment discontinuation. The model includes predictor variables representing demographics (gender, age, region, plan type, beneficiary status), pre-treatment physical health comorbidities (Charlson score), pre-treatment mental health comorbidities (schizophrenia, bipolar, major depression, anxiety), and pre-treatment drug use disorders.

^**

Indicates p < 0.01